Toxicities associated with lymphoma-targeting bispecific antibodies—a review
Bispecific antibodies (bsAbs) are an emerging class of directed immunotherapies with established uses in certain hematological malignancies as well as an emerging role in the treatment of solid organ malignancy. These molecules are able to juxtapose T cells (in most cases) with target tumor cells, f...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1582975/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849416604430893056 |
|---|---|
| author | Christopher Doig Costas Kleanthes Yannakou Costas Kleanthes Yannakou |
| author_facet | Christopher Doig Costas Kleanthes Yannakou Costas Kleanthes Yannakou |
| author_sort | Christopher Doig |
| collection | DOAJ |
| description | Bispecific antibodies (bsAbs) are an emerging class of directed immunotherapies with established uses in certain hematological malignancies as well as an emerging role in the treatment of solid organ malignancy. These molecules are able to juxtapose T cells (in most cases) with target tumor cells, forming an immunological synapse. bsAbs are under extensive investigation in the treatment of B-cell non-Hodgkin lymphomas, with encouraging results in both the monotherapy and combination therapy settings. In this review we summarize the key toxicities associated with the use of lymphoma-targeting bsAbs: cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, cytopenias, infections and immunosuppression as well as tumor lysis syndrome. While the toxicities are not insignificant, they are typically manageable and justifiable given the unmet medical need, especially in the case of relapsed or refractory disease. |
| format | Article |
| id | doaj-art-5ccffc0661a047c9b6f706b8f652a78b |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-5ccffc0661a047c9b6f706b8f652a78b2025-08-20T03:33:08ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-07-011210.3389/fmed.2025.15829751582975Toxicities associated with lymphoma-targeting bispecific antibodies—a reviewChristopher Doig0Costas Kleanthes Yannakou1Costas Kleanthes Yannakou2Department of Molecular Oncology and Cancer Immunology, Epworth HealthCare, Melbourne, VIC, AustraliaDepartment of Molecular Oncology and Cancer Immunology, Epworth HealthCare, Melbourne, VIC, AustraliaDepartment of Clinical Pathology, The University of Melbourne, Parkville, VIC, AustraliaBispecific antibodies (bsAbs) are an emerging class of directed immunotherapies with established uses in certain hematological malignancies as well as an emerging role in the treatment of solid organ malignancy. These molecules are able to juxtapose T cells (in most cases) with target tumor cells, forming an immunological synapse. bsAbs are under extensive investigation in the treatment of B-cell non-Hodgkin lymphomas, with encouraging results in both the monotherapy and combination therapy settings. In this review we summarize the key toxicities associated with the use of lymphoma-targeting bsAbs: cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, cytopenias, infections and immunosuppression as well as tumor lysis syndrome. While the toxicities are not insignificant, they are typically manageable and justifiable given the unmet medical need, especially in the case of relapsed or refractory disease.https://www.frontiersin.org/articles/10.3389/fmed.2025.1582975/fullBsAbbispecific antibodyCRScytokine release syndromeICANSimmune effector cell-associated neurotoxicity syndrome |
| spellingShingle | Christopher Doig Costas Kleanthes Yannakou Costas Kleanthes Yannakou Toxicities associated with lymphoma-targeting bispecific antibodies—a review Frontiers in Medicine BsAb bispecific antibody CRS cytokine release syndrome ICANS immune effector cell-associated neurotoxicity syndrome |
| title | Toxicities associated with lymphoma-targeting bispecific antibodies—a review |
| title_full | Toxicities associated with lymphoma-targeting bispecific antibodies—a review |
| title_fullStr | Toxicities associated with lymphoma-targeting bispecific antibodies—a review |
| title_full_unstemmed | Toxicities associated with lymphoma-targeting bispecific antibodies—a review |
| title_short | Toxicities associated with lymphoma-targeting bispecific antibodies—a review |
| title_sort | toxicities associated with lymphoma targeting bispecific antibodies a review |
| topic | BsAb bispecific antibody CRS cytokine release syndrome ICANS immune effector cell-associated neurotoxicity syndrome |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1582975/full |
| work_keys_str_mv | AT christopherdoig toxicitiesassociatedwithlymphomatargetingbispecificantibodiesareview AT costaskleanthesyannakou toxicitiesassociatedwithlymphomatargetingbispecificantibodiesareview AT costaskleanthesyannakou toxicitiesassociatedwithlymphomatargetingbispecificantibodiesareview |